Current antipsychotic therapy and metabolic syndrome

The paper presents the data of examining 50 patients with paranoid schizophrenia (according to the ICD-10 criteria) and type 2 diabetes mellitus (T2DM). Group 1 comprised patients receiving haloperidol; Group 2 included patients taking atypical neuroleptics. To study latent carbohydrate metabolic disturbances occurring in the use of atypical neuroleptics, the investigators examined 50 patients with their first lifetime psychotic state that met the ICD-10 criteria for paranoid schizophrenia, who had no metabolic disturbances and had received no antipsychotic therapy before inclusion into the study. These patients were randomized into 2 groups, by administering atypical antipsychotics or haloperidol. Their examination involved clinical, catamnestic, biochemical, and anthropometric studies. The paper considers various aspects of the metabolic disturbances occurring in paranoid schizophrenics during current antipsychotic therapy. Trends in the development of T2DM during therapy with classical and atypical neuroleptics are comparatively analyzed. The authors show it possible to use an oral glucose tolerance test to identify latent carbohydrate metabolic disturbances in patients with paranoid schizophrenia during current antipsychotic therapy.

diabetes mellitus, dyslipidemia, atypical antipsychotics, metabolic syndrome, paranoid schizophrenia